Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092577 | 1.00 | POLB (0.37) | POLBTRPM5HDAC1HDAC2HDAC6 | |
| SCHEMBL725021 | 0.86 | HDAC1 (0.44) | HDAC1HDAC2HDAC6 | |
| SCHEMBL725024 | 0.86 | HDAC1 (0.44) | HDAC1HDAC2HDAC6 | |
| SCHEMBL1092789 | 0.84 | POLB (0.37) | POLBHDAC1HDAC2HDAC6 | |
| SCHEMBL2276122 | 0.84 | POLB (0.37) | POLBHDAC1HDAC2HDAC6 | |
| SCHEMBL725263 | 0.84 | POLB (0.37) | POLBHDAC1HDAC2HDAC6 | |
| SCHEMBL725798 | 0.84 | POLB (0.37) | POLBHDAC1HDAC2HDAC6 | |
| SCHEMBL725232 | 0.84 | POLB (0.37) | POLBHDAC1HDAC2HDAC6 | |
| SCHEMBL1094316 | 0.84 | POLB (0.37) | POLBHDAC1HDAC2HDAC6 | |
| SCHEMBL726114 | 0.83 | POLB (0.38) | POLBCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560584-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-01-14 | — | — | EP | claimed |
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | claimed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2579863-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | Affinium Pharmaceuticals, Inc. (CA) | 2013-04-17 | — | — | EP | disclosed |
| US-8153652-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-04-10 | — | — | US | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| WO-2011156811-A2 | COMPOUNDS FOR TREATMENT OF BOVINE MASTITIS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-12-15 | — | — | WO | disclosed |
| US-20110098277-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-7741339-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-20090221699-A1 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | DEBIOPHARM INTERNATIONAL SA (CH) | 2009-09-03 | — | — | US | disclosed |
| EP-1560584-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| EP-1608377-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARM INC (CA) | 2008-10-01 | — | — | EP | disclosed |
| US-7250424-B2 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2007-07-31 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
| US-20060116394-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2006-06-01 | — | — | US | disclosed |
| US-7049310-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-05-23 | — | — | US | disclosed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221699-A1 | E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide, useful in the treatment bacterial infections. | ACR, NANP, MDN1 | POLB 971/4885TRPM5 3603/4885HDAC1 735/4885 |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | POLB 2413/4885TRPM5 1394/4885HDAC1 488/4885 |
| US-20060116394-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI2 | POLB 745/4885TRPM5 4016/4885HDAC1 97/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | POLB 851/4885TRPM5 3999/4885HDAC1 82/4885 |
| US-20040147580-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI1 | POLB 629/4885TRPM5 4067/4885HDAC1 77/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | POLB 851/4885TRPM5 3999/4885HDAC1 82/4885 |
| US-20110098277-A1 | Fab I Inhibitors | SERPINB1, TMBIM6, GDI2 | POLB 745/4885TRPM5 4016/4885HDAC1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.